The Heritage Program

The Heritage program reads the polygenic profile of a pre-implantation embryo and produces a report against the same axes of biology we interpret for adult users: polygenic risk for major heritable conditions, trait predictors backed by peer-reviewed evidence, clinical variant calls across the ClinVar and ACMG corpora, pharmacogenomic star-allele predictions for future medication response, and, for variants not yet classified, interpretation via DNA foundation models. The report is delivered to the fertility clinic handling the cycle, reviewed alongside traditional PGT results by a licensed genetic counselor, and discussed with the parents through that clinician — never directly, never absent clinical context.

Every output is probability, not certainty. Every recommendation is guidance, not prescription. Every report is bounded by what the biology, as currently understood, can justify.

We name the most common misconceptions explicitly so the conversation can be cleaner downstream.

• This is not “designer baby” software. We do not offer selection on traits unsupported by peer-reviewed scientific evidence. We do not accept applications framed around cosmetic preference or speculative enhancement.
• This is not a direct-to-consumer service. You cannot subscribe to this program. It operates only inside a supervised IVF cycle at a partner clinic, with a licensed genetic counselor involved.
• This is not deterministic. Polygenic scores predict probability distributions across populations, not certainties for individuals. A recommended embryo can still develop a condition; a non-recommended embryo can still be healthy. We communicate this clearly in every report.
• This is not universally available. Legal frameworks for pre-implantation polygenic analysis vary substantially by jurisdiction. We operate only where the practice is lawful and only through clinics authorized to perform it.
• This is not a replacement for standard PGT. We are the polygenic interpretation layer. Traditional preimplantation genetic testing (aneuploidy, monogenic disease screening) is performed by the clinic using established methods, and our report supplements it.

Three groups it is built for. Each can join the waiting list now.

Heritage is not a separate service with a bespoke contract. It is a feature of the Haeckel platform, alongside the rest of the genome work.

Offspring modeling already lives in the platform and can be explored as a demo today: combine two genomes, project inheritance across polygenic methods, and compare profiles side by side. The supervised clinical layer, polygenic embryo analysis delivered to a partner clinic and reviewed by a licensed genetic counselor, opens in January 2027 in jurisdictions where it is lawful.

Until then there is a waiting list, not an application. Join it and we will reach out as launch approaches, with the clinical pathway, timing, and jurisdiction review for your situation. When it opens, engagement runs through a written agreement between your clinic and Heru Genomics Inc., with clear scope, data flow, privacy terms, and a clinical handoff protocol.

These are the conditions under which we will decline. We state them publicly so the filtering happens before contact, not after.

• Jurisdictional prohibition. If your country or state prohibits or does not recognize polygenic preimplantation analysis, we cannot operate there.
• Unsupported trait requests. Requests framed around selection for traits without strong peer-reviewed evidence (cosmetic, behavioral-speculative, socially-coded traits that do not map to well-validated biology) will be declined.
• Clinical context missing. Requests outside a supervised IVF cycle will be declined. We do not bypass fertility clinics.
• Intent misalignment. If a request frames this work outside health, informed consent, and clinical supervision, we decline.
• Absence of genetic counselor. Every engagement requires a licensed genetic counselor — either provided by the clinic or, in select partnerships, facilitated by us. We do not operate without that role filled.

The history of directed intervention in human biology is not spotless. Neither is the history of refusing to attempt it when the cost of refusal was measured in suffering. The serious work — the work Haeckel is attempting — is done by people who hold both truths at once.

Polygenic scores for embryo analysis are an emerging field. The scientific literature is active, with peer-reviewed evidence supporting analysis for certain heritable conditions and significant debate around others. Haeckel's position is to offer analysis only where the evidence is established, to communicate uncertainty plainly in every report, and to evolve the scope of what we offer as the science evolves — never ahead of it.

We welcome critique from the field. Our methods are available for inspection by peer reviewers under NDA, and we intend to publish methodology and validation results as the program matures.

All Haeckel outputs, including those produced under the Heritage program, are provided for research and clinical-decision-support purposes. Haeckel is not a medical device. The final clinical decision in any IVF cycle rests with the patient and their attending physician. Haeckel's reports supplement but do not replace genetic counseling or medical judgment.